Privitera, Giuseppe
Privitera, Giuseppe
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study
2022 Pugliese, Daniela; Privitera, Giuseppe; Crispino, Federica; Mezzina, Nicolò; Castiglione, Fabiana; Fiorino, Gionata; Laterza, Lucrezia; Viola, Antonella Anna Paola; Bertani, Lorenzo; Caprioli, Flavio; Cappello, Maria; Barberio, Brigida; Ricci, Chiara; Balestrieri, Paola; Daperno, Marco; Pluchino, Dario; Rizzello, Fernando; Scribano, Maria Lia; Sablich, Renato; Pastorelli, Luca; Manguso, Francesco; Variola, Angela; Di Sario, Antonio; Grossi, Laurino; Armuzzi, Alessandro; Null, Null
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study.
2022 Papa, A; Scaldaferri, F; Covino, M; Tursi, A; Furfaro, F; Mocci, G; Lopetuso, Lr; Maconi, G; Bibbò, S; Fiorani, M; Laterza, L; Mignini, I; Napolitano, D; Parisio, L; Pizzoferrato, M; Privitera, G; Pugliese, D; Schepis, T; Schiavoni, E; Settanni, Cr; Vetrone, Lm; Armuzzi, A; Danese, S; Gasbarrini, A.
Novel Insights Into the Interactions Between the Gut Microbiome, Inflammasomes, and Gasdermins During Colorectal Cancer
2022 Privitera, Giuseppe; Rana, N.; Scaldaferri, Franco; Armuzzi, Alessandro; Pizarro, T. T.
Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence
2021 Cesario, Alfredo; D'Oria, Marika; Bove, Francesco; Privitera, Giuseppe; Boskoski, Ivo; Pedicino, Daniela; Boldrini, Luca; Erra, Carmen; Loreti, Claudia; Liuzzo, Giovanna; 7, Filippo Crea; Armuzzi, Alessandro; Gasbarrini, Antonio; Calabresi, Paolo; Padua, Luca; Costamagna, Guido; Antonelli, Massimo; Valentini, Vincenzo; Auffray, Charles; Scambia, Giovanni
Predictors and early markers of response to biological therapies in inflammatory bowel diseases
2021 Privitera, Giuseppe; Pugliese, Daniela; Rapaccini, Gian Ludovico; Gasbarrini, Antonio; Armuzzi, Alessandro; Guidi, Luisa
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients
2021 Pugliese, Daniela; Guidi, Luisa; Privitera, Giuseppe; Bertani, L.; Tolusso, Barbara; Papparella, Luigi Giovanni; Maltinti, S.; Di Mario, Clara; Onali, Sebastiano; Ceccarelli, L.; Rapaccini, Gian Ludovico; Scaldaferri, Franco; Gremese, Elisa; Gasbarrini, Antonio; Costa, F.; Armuzzi, Alessandro
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients
2021 Pugliese, Daniela; Guidi, Luisa; Privitera, Giuseppe; Bertani, L.; Tolusso, Barbara; Papparella, Luigi Giovanni; Maltinti, S.; Di Mario, Clara; Onali, Sebastiano; Ceccarelli, L.; Rapaccini, Gian Ludovico; Scaldaferri, Franco; Gremese, Elisa; Gasbarrini, Antonio; Costa, F.; Armuzzi, Alessandro
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19
2021 Napolitano, Daniele; Privitera, Giuseppe; Schiavoni, Elisa; Turchini, Laura; Amatucci, V.; Pugliese, Daniela; Gasbarrini, Antonio; Scaldaferri, Franco; Armuzzi, Alessandro
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease
2020 Privitera, Giuseppe; Onali, Sara; Pugliese, Daniela; Renna, Sara; Savarino, Edoardo; Viola, Antonella Anna Paola; Ribaldone, Davide Giuseppe; Buda, Andrea; Bezzio, Cristina; Fiorino, Gionata; Fantini, Massimo Claudio; Scaldaferri, Franco; Guidi, Luisa; Danese, Silvio; Gasbarrini, Antonio; Orlando, Ambrogio; Armuzzi, Alessandro
| Data di pubblicazione | Titolo | Autore(i) | File |
|---|---|---|---|
| 1-gen-2022 | Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study | Pugliese, Daniela; Privitera, Giuseppe; Crispino, Federica; Mezzina, Nicolò; Castiglione, Fabiana; Fiorino, Gionata; Laterza, Lucrezia; Viola, Antonella Anna Paola; Bertani, Lorenzo; Caprioli, Flavio; Cappello, Maria; Barberio, Brigida; Ricci, Chiara; Balestrieri, Paola; Daperno, Marco; Pluchino, Dario; Rizzello, Fernando; Scribano, Maria Lia; Sablich, Renato; Pastorelli, Luca; Manguso, Francesco; Variola, Angela; Di Sario, Antonio; Grossi, Laurino; Armuzzi, Alessandro; Null, Null | |
| 1-gen-2022 | Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. | Papa, A; Scaldaferri, F; Covino, M; Tursi, A; Furfaro, F; Mocci, G; Lopetuso, Lr; Maconi, G; Bibbò, S; Fiorani, M; Laterza, L; Mignini, I; Napolitano, D; Parisio, L; Pizzoferrato, M; Privitera, G; Pugliese, D; Schepis, T; Schiavoni, E; Settanni, Cr; Vetrone, Lm; Armuzzi, A; Danese, S; Gasbarrini, A. | |
| 1-gen-2022 | Novel Insights Into the Interactions Between the Gut Microbiome, Inflammasomes, and Gasdermins During Colorectal Cancer | Privitera, Giuseppe; Rana, N.; Scaldaferri, Franco; Armuzzi, Alessandro; Pizarro, T. T. | |
| 1-gen-2021 | Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence | Cesario, Alfredo; D'Oria, Marika; Bove, Francesco; Privitera, Giuseppe; Boskoski, Ivo; Pedicino, Daniela; Boldrini, Luca; Erra, Carmen; Loreti, Claudia; Liuzzo, Giovanna; 7, Filippo Crea; Armuzzi, Alessandro; Gasbarrini, Antonio; Calabresi, Paolo; Padua, Luca; Costamagna, Guido; Antonelli, Massimo; Valentini, Vincenzo; Auffray, Charles; Scambia, Giovanni | |
| 1-gen-2021 | Predictors and early markers of response to biological therapies in inflammatory bowel diseases | Privitera, Giuseppe; Pugliese, Daniela; Rapaccini, Gian Ludovico; Gasbarrini, Antonio; Armuzzi, Alessandro; Guidi, Luisa | |
| 1-gen-2021 | Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients | Pugliese, Daniela; Guidi, Luisa; Privitera, Giuseppe; Bertani, L.; Tolusso, Barbara; Papparella, Luigi Giovanni; Maltinti, S.; Di Mario, Clara; Onali, Sebastiano; Ceccarelli, L.; Rapaccini, Gian Ludovico; Scaldaferri, Franco; Gremese, Elisa; Gasbarrini, Antonio; Costa, F.; Armuzzi, Alessandro | |
| 1-gen-2021 | Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients | Pugliese, Daniela; Guidi, Luisa; Privitera, Giuseppe; Bertani, L.; Tolusso, Barbara; Papparella, Luigi Giovanni; Maltinti, S.; Di Mario, Clara; Onali, Sebastiano; Ceccarelli, L.; Rapaccini, Gian Ludovico; Scaldaferri, Franco; Gremese, Elisa; Gasbarrini, Antonio; Costa, F.; Armuzzi, Alessandro | |
| 1-gen-2021 | The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 | Napolitano, Daniele; Privitera, Giuseppe; Schiavoni, Elisa; Turchini, Laura; Amatucci, V.; Pugliese, Daniela; Gasbarrini, Antonio; Scaldaferri, Franco; Armuzzi, Alessandro | |
| 1-gen-2020 | Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease | Privitera, Giuseppe; Onali, Sara; Pugliese, Daniela; Renna, Sara; Savarino, Edoardo; Viola, Antonella Anna Paola; Ribaldone, Davide Giuseppe; Buda, Andrea; Bezzio, Cristina; Fiorino, Gionata; Fantini, Massimo Claudio; Scaldaferri, Franco; Guidi, Luisa; Danese, Silvio; Gasbarrini, Antonio; Orlando, Ambrogio; Armuzzi, Alessandro |